125 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) each “employee benefit plan” (within the meaning of Section 3(3) of the Employee … .
(vv) Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee, affiliate or other person
S-8
a9gxbzrw337tklluf
31 Jan 24
Registration of securities for employees
4:19pm
8-K
EX-10.1
fv1eigyqns9fpy6 f6
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
8-K
6fyjl60x c8k5d8moia
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
S-8
ibst wm3l0ixnltlyftf
17 Jan 24
Registration of securities for employees
4:06pm
S-3ASR
1a9ykm0t2q3fu
2 Jan 24
Automatic shelf registration
4:06pm
S-3ASR
EX-4.3
ks54 6u1111of
2 Jan 24
Automatic shelf registration
4:06pm
144
31ba5t960z
14 Dec 23
Notice of proposed sale of securities
5:09pm
8-K
EX-1.1
pexr8fo5mjrp5
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
s9ox7vxa
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.2
npa id3sft
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
753wk n6n
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
al4lahj
27 Sep 23
Prospectus supplement for primary offering
5:26pm